Antibody Drug Conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. The antibody part of the ADC specifically targets cancer cells, while the drug component kills those cells. The conjugation of these two components is a crucial area of research involving various catalytic processes.
